Celcuity’s Q3 2025 Playbook: Gedatolisib, ESMO Glimmers, and the FDA NDA Mile Marker

Celcuity reported its third quarter of 2025 with a corporate update centered on its PI3K pathway program, gedatolisib, and strategic timing around regulatory milestones. The release highlights early clinical progress from the Phase 3 VIKTORIA-1 trial, including efficacy and safety discussions from the PIK3CA wild-type cohort presented at the European Society for Medical Oncology (ESMO) meeting, as well as ongoing development activities in combination regimens. The company also anchors near-term milestones—topline data for the PIK3CA mutant cohort expected in late Q1 2026 or during Q2 2026 and a New Drug Application (NDA) submission to the FDA for gedatolisib anticipated in Q4 2025.

Key milestones and clinical milestones

• ESMO presentation of detailed efficacy and safety results for the PIK3CA wild-type cohort from the VIKTORIA-1 Phase 3 trial.
• Phase 1b data for gedatolisib in combination with Nubeqa (darolutamide) in metastatic castration-resistant prostate cancer highlighted at a poster session at ESMO.
• Enrollment complete for the PIK3CA mutant cohort of VIKTORIA-1; topline data expected late Q1 2026 or during Q2 2026.
• NDA submission for gedatolisib, based on PIK3CA wild-type data, on track for completion in Q4 2025.
• Management webcast and conference call scheduled for November 12, 2025, to discuss quarterly results and strategic updates.

Clinical significance and strategic reading

The company’s narrative stresses a potential pathway to regulatory submission tied to the PIK3CA wild-type cohort—an angle that, if validated, could differentiate gedatolisib within the PI3K inhibitor space. The emphasis on ESMO data, coupled with an NDA timeline, frames a narrative where clinical momentum dovetails with regulatory prospects. That linkage matters for the stock’s narrative as investors weigh not just the raw numbers but the cadence of milestones that could unlock downstream value.

From a sector perspective, Celcuity’s bet on combining gedatolisib with established antiandrogens outside breast cancer—such as darolutamide in prostate cancer—highlights a broader pharma trend: pairing selective PI3K pathway inhibitors with other targeted therapies to bolster efficacy while managing safety. In a field where “EPS” and “revenue forecast” are often secondary to milestone-driven licensing and potential NDA outcomes, CELC’s path will be judged on data density, safety signals, and the cadence of regulatory interactions as much as on quarterly revenue and earnings metrics.

Financials, EPS, and the earnings narrative

As a clinical-stage biotech, Celcuity’s near-term earnings profile is typically driven by headcount, R&D spend, and regulatory milestones more than by traditional revenue streams. The press release focuses on pipeline progress and regulatory timing rather than presenting a detailed EPS figure or a clean revenue forecast. In practice, investors will watch for EPS and revenue surprises—or the lack thereof—in the upcoming quarterly results. Until then, the relevance of EPS consensus remains the question: do analysts anticipate a modest negative quarterly print tied to operating burn, or is consensus expectations shifting if the NDA trigger looms closer?

Bottom line for the earnings narrative: the market will read any quarterly release through the lens of the NDA timeline and milestone-driven catalysts. A modest negative EPS is common for early-stage biotech, but signs of progress toward a regulatory submission and a clear pipeline trajectory can offset purely financial headwinds in the near term.

What to watch next for CELC and peers

• NDA timing for gedatolisib remains a focal point. If the Q4 2025 target holds, investors will recalibrate their EPS and revenue expectations around potential commercial milestones, not just clinical readouts.
• topline data for the PIK3CA mutant cohort in early 2026 will be a critical inflection point, potentially altering how analysts model the program’s peak sales potential and the likelihood of new indications.
• ESMO data continues to shape the competitive narrative for PI3K inhibitors; peers pursuing similar targets will be watching gauge risks related to safety signals and durability of response.
• Analysts will likely issue EPS consensus revisions and revenue forecasts as clarity on regulatory milestones crystallizes, affecting the stock’s multiple and implied probability-weighted outcomes.

Implications for the sector

Celcuity’s progress underscores a broader pattern: biotech firms with targeted PI3K–mTOR pathway assets are increasingly reliant on a blend of robust clinical data and regulatory timing to create equity value. For sector peers, the enduring question is whether these programs can translate early-stage signals into durable clinical advantage and, crucially, whether the regulatory path can unlock a sustainable commercial plan. In other words, investors are not just betting on a single trial—but on the timing of a regulatory green light and the ability to convert trial data into a revenue story, a difficult conversion in an era of rising development costs and crowded pipelines.

Conclusion: A measured optimism with a calendar in hand

Celcuity’s Q3 2025 update sketches a plausible route to an FDA NDA that could unlock meaningful value if the VIKTORIA-1 data land as hoped and topline readouts in 2026 validate the wild-type and mutant cohorts. In the meantime, the stock narrative will hinge on a few levers: EPS expectations evolving in lockstep with the NDA timeline, cargo of data readouts from ESNO/ESMO, and the ever-present risk-reward calculus of oncology commercialization. While a tidy profit line may still be distant, the company’s execution on milestones and the sequencing of regulatory milestones could tilt sentiment in CELC’s favor—and ripple through peers chasing the same regulatory milestones in the PI3K inhibitor arena.